Disease Domain | Count |
---|---|
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 3 |
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Antibody drug conjugate (ADC) | 1 |
Top 5 Target | Count |
---|---|
CEBPB x FASN x PPARα/γ x STMN3 | 1 |
PDL1 x Top II | 1 |
E2F1 x MUC4 x PTEN | 1 |
CTNNB1(Catenin beta 1) | 1 |
Mechanism CEBPB inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CTNNB1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Oct 2024 |
Sponsor / Collaborator |
Start Date13 Jun 2024 |
Sponsor / Collaborator |
Start Date21 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CWP232228 ( CTNNB1 ) | Colonic Cancer More | Preclinical |
PD-L1-AuNP-DOX ( PDL1 x Top II ) | Colorectal Cancer More | Preclinical |
Thymoquinone ( E2F1 x MUC4 x PTEN ) | Kidney Neoplasms More | Preclinical |
KMU-3 ( CEBPB x FASN x PPARα/γ x STMN3 ) | Obesity More | Preclinical |